Does Breast Cancer Surgery Initiate Relapse, What Is the Evidence and How May This Be Arrested?

Dear Colleagues,

Breast cancer is the most pressing cancer concern in the world for women. There have been significant improvements in the early detection and treatment of breast cancer, but it remains a very serious unsolved problem. There are 2 million new diagnoses annually in the world. In the US, 255,000 women are diagnosed with breast cancer and 42,000 women die from the disease yearly. This Special Issue proposes a remarkably different method of treating early-stage breast cancer. The estimated benefit could be as much as 25 to 50% at very little cost and toxicity. This has been confirmed in retrospective studies but not as yet in clinical trials.

This project started in a very unusual manner. In 1993, Dr. Demicheli presented data from Milan that showed a bimodal relapse pattern. The Milan data are considered very high quality, so these data were striking. Dr. Retsky happened to see those data and was quite intrigued particularly after surgeon Michael Baum discussed bimodal relapse data from the UK.

In this Special Issue, we describe our collaborative research to try and understand the meaning of the early and later relapses. This led us on a trail that crossed several medical boundaries and has been going on since 1993. We now include physicians with specialties in surgery, medical oncology and anesthesiology. Scientists include blood disease experts and a physicist with skills in computer simulation.

Papers are invited that discuss topics relevant to the Retsky, Hrushesky, Erhabor, et al. Special Issue document. Such papers need to be submitted by Dec 1, 2022.

Dr. Michael W. Retsky
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.